FindTrial
Sign In

ALECSAT

BIOLOGICAL6 trials

Sponsors

CytoVac A/S, Henrik Ditzel

Conditions

Breast CancerGlioblastomaGlioblastoma MultiformeHormone-refractory Prostate CancerMetastatic Breast CancerPancreatic CancerTriple Negative Breast Cancer

Phase 1

Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
CompletedNCT00891345
CytoVac A/SHormone-refractory Prostate Cancer
Start: 2009-04-30End: 2010-07-31Updated: 2012-04-27
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
CompletedNCT01422850
CytoVac A/SHormone-refractory Prostate Cancer
Start: 2011-08-31End: 2012-10-31Updated: 2014-04-23
A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients
CompletedNCT01984658
CytoVac A/SPancreatic Cancer
Start: 2013-10-31End: 2015-09-30Updated: 2019-02-26
ImmunoBreast - A Phase Ib Study
NCT04609215
Henrik DitzelBreast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer
Start: 2020-04-21End: 2023-05-21Target: 20Updated: 2022-04-20

Phase 2

Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
TerminatedNCT02060955
CytoVac A/SGlioblastoma Multiforme
Start: 2014-02-28End: 2015-07-31Updated: 2016-06-06
Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
CompletedNCT02799238
CytoVac A/SGlioblastoma
Start: 2016-03-31End: 2020-02-24Updated: 2020-04-30

Related Papers

Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial.
2025-12-04